on ABSCIENCES (EPA:AB)
AB Science: Update on the Clinical Program and Strategic Suspension
AB Science has secured €25 million in clinical trial insurance for its Phase III study in amyotrophic lateral sclerosis (ALS). This financial risk transfer protects shareholders' capital in the event of clinical failure. The policy covers costs up to a total of €39 million, demonstrating investor confidence in masitinib, the potential treatment for ALS.
In parallel, AB Science has decided to voluntarily and temporarily suspend its clinical trials in Europe. This is part of a strategic reorganization and resource prioritization effort, in response to concerns raised by European health authorities. This decision does not affect the company's current operations but reflects a refocusing on its core programs.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABSCIENCES news